Updated

Sandoz CEO Richard Saynor warned that proposed U.S. tariffs on imported generic drugs under the Trump administration could force manufacturers to raise prices or cut supply, ultimately passing costs onto patients. Saynor said steep tariffs on generics, which typically operate on thin margins, would be especially damaging given the essential nature of the medications. The warning adds to growing pushback from pharmaceutical executives against tariff proposals targeting the drug industry, as companies caution that such measures could strain already fragile generic drug supply chains.